Physician profile
David B Wilhelm
NPI 1134155195
$15,445.77
in general payments reported to CMS, 2019-2025
63 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $2,135 · 2021: $2,755 · 2022: $3,385 · 2023: $2,056 · 2024: $1,897 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,582 · Travel and Lodging: $193 · Entertainment: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,582.41 |
| Travel and Lodging | $193.12 |
| Entertainment | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,259.35 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,965.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,473.94 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Amgen INC. | $1,078.42 | 2019-2025 | Repatha, Otezla, Aimovig |
| Bayer Healthcare Pharmaceuticals INC. | $977.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $855.90 | 2019-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $547.62 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $488.19 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $457.79 | 2019-2023 | Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $426.84 | 2019-2024 | Trintellix |
| Abbott Laboratories | $409.96 | 2019-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $380.49 | 2019-2025 | |
| Allergan, INC. | $366.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $317.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $282.41 | 2020-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.